Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Amerika
Viatris Inc
Nieuws
Viatris Inc
VTRS
NAS
: VTRS
| ISIN: US92556V1061
20/05/2024
11,07 USD
(+0,82%)
(+0,82%)
20/05/2024
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Dividend
Technische analyse
TA
Toon enkel gratis nieuws
9 mei 2024 ·
Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges
· Persbericht
2 mei 2024 ·
Viatris to Participate in the BofA Securities 2024 Health Care Conference
· Persbericht
1 mei 2024 ·
Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health
· Persbericht
16 april 2024 ·
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024
· Persbericht
15 april 2024 ·
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
· Persbericht
1 april 2024 ·
Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States
· Persbericht
27 maart 2024 ·
Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline
· Persbericht
28 februari 2024 ·
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
· Persbericht
28 februari 2024 ·
Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration
· Persbericht
5 februari 2024 ·
Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results
· Persbericht
21 december 2023 ·
Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference
· Persbericht
15 december 2023 ·
Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer
· Persbericht
15 december 2023 ·
Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders
· Persbericht
13 november 2023 ·
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
· Persbericht
7 november 2023 ·
Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1]
· Persbericht
30 oktober 2023 ·
Viatris to Host Webinar: The Power of Partnership to Address Antimicrobial Resistance
· Persbericht
23 oktober 2023 ·
Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row
· Persbericht
20 oktober 2023 ·
Rajiv Malik to Retire as President of Viatris Effective April 1, 2024
· Persbericht
18 oktober 2023 ·
Viatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking
· Persbericht
10 oktober 2023 ·
Viatris to Release Third Quarter 2023 Financial Results on November 7, 2023
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe